BRPI0613631A8 - nanoemulsão e método, - Google Patents

nanoemulsão e método,

Info

Publication number
BRPI0613631A8
BRPI0613631A8 BRPI0613631A BRPI0613631A BRPI0613631A8 BR PI0613631 A8 BRPI0613631 A8 BR PI0613631A8 BR PI0613631 A BRPI0613631 A BR PI0613631A BR PI0613631 A BRPI0613631 A BR PI0613631A BR PI0613631 A8 BRPI0613631 A8 BR PI0613631A8
Authority
BR
Brazil
Prior art keywords
nanoemulsions
nanoemulsion
compound
improved
uniform
Prior art date
Application number
BRPI0613631A
Other languages
English (en)
Inventor
Nicolosi Robert
Wilson Thomas
Original Assignee
Univ Massachusetts Lowell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts Lowell filed Critical Univ Massachusetts Lowell
Publication of BRPI0613631A2 publication Critical patent/BRPI0613631A2/pt
Publication of BRPI0613631A8 publication Critical patent/BRPI0613631A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/40—Mixing liquids with liquids; Emulsifying
    • B01F23/41—Emulsifying
    • B01F23/413—Homogenising a raw emulsion or making monodisperse or fine emulsions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

nanoemulsão, metodo, e, uso de um composto e de uma nanoemulsão a presente invenção apresenta uma nanoemulsão melhorada composta de uma faixa uniforme e distinta de diâmetros de partículas muito pequenas com tamanho nano. esta uniformidade resulta em uma biodisponibilidade melhorada dos compostos incorporados (i.e., farmacêuticos ou nutracêuticos) conforme refletido em vários parâmetros fármaco-cinéticos, incluindo, mas não limitados a, tmax reduzida, cmax aumentada, e auc aumentada. o método melhorado de produção destas nanoemulsões uniformes utiliza microfluidização, que é diferente, tanto no processo como na mecânica, quando comparado com as técnicas convencionais de moagem e trituração usadas para gerar composições de nanopartículas. além disso, a melhoria resulta, em parte, de uma etapa nova de mistura de um composto substancialmente solúvel em um meio de dispersão aquecido. isto é diferente dos métodos atuais de composição de nanopartículas que misturam um composto insolúvel com um meio de dispersão não aquecido. além disso, observou-se que estas nanoemulsões sãoresistentes a bactérias e são estáveis em extremos, tanto de alterações de temperatura como de pil. em conseqúência, espera-se que estas nanoemulsões tenham uma vida de prateleira mais significativamenteprolongada do que as nanoemulsões disponíveis atualmente.
BRPI0613631A 2005-07-18 2006-07-11 nanoemulsão e método, BRPI0613631A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70022405P 2005-07-18 2005-07-18
US60/700224 2005-07-18
PCT/US2006/026918 WO2008010788A2 (en) 2005-07-18 2006-07-11 Compositions and methods for making and using nanoemulsions

Publications (2)

Publication Number Publication Date
BRPI0613631A2 BRPI0613631A2 (pt) 2011-01-18
BRPI0613631A8 true BRPI0613631A8 (pt) 2017-12-26

Family

ID=38957224

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0613631A BRPI0613631A8 (pt) 2005-07-18 2006-07-11 nanoemulsão e método,

Country Status (10)

Country Link
US (2) US20080274195A1 (pt)
EP (1) EP1919447A4 (pt)
JP (2) JP5368793B2 (pt)
KR (2) KR20130079645A (pt)
CN (2) CN101384247B (pt)
AU (1) AU2006346369B2 (pt)
BR (1) BRPI0613631A8 (pt)
CA (1) CA2618655C (pt)
IL (2) IL188666A (pt)
WO (1) WO2008010788A2 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006036982A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Drug delivery coating for use with a stent
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
WO2006036969A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Formation of barrier layer
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
CA2618655C (en) 2005-07-18 2015-12-22 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
WO2007035311A2 (en) * 2005-09-16 2007-03-29 University Of Massachusetts Lowell Anti-oxidant synergy formulation nanoemulsions to treat cancer
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
DK3144013T3 (en) 2005-12-01 2019-03-04 Univ Massachusetts Lowell Botulinum nanoemulsions
US20100183726A1 (en) * 2006-08-02 2010-07-22 Robert Nicolosi Compositions and methods for treating cancer with dacarbazine nanoemulsions
WO2008057328A2 (en) 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US20080124387A1 (en) * 2006-11-27 2008-05-29 Kapac, Llc Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients
BRPI0719732A2 (pt) 2006-12-01 2017-05-16 Anterios Inc nanopartículas de peptídeo e usos para as mesmas
BRPI0719756A2 (pt) 2006-12-01 2014-01-21 Anterios Inc Nanopartículas de entidades anfifílicas
KR20100050443A (ko) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
US8357639B2 (en) 2007-07-03 2013-01-22 Baker Hughes Incorporated Nanoemulsions
JP5101193B2 (ja) * 2007-07-06 2012-12-19 富士フイルム株式会社 化粧品組成物
WO2009014452A1 (en) * 2007-07-25 2009-01-29 Epax As Omega-3 fatty acid fortified composition
EP2548456B1 (en) 2008-03-20 2015-07-08 Virun, Inc. Emulsions including a PEG-derivative of tocopherol
CA2719803A1 (en) * 2008-03-28 2009-10-01 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US20110045050A1 (en) * 2009-08-24 2011-02-24 Atrium Medical Corporation Nanoemulsion formulations for direct delivery
ITBS20100017A1 (it) * 2010-02-03 2011-08-04 Francesco Palladini Procedimento per la produzione di un integratore alimentare ed integratore cosi' ottenuto
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
US8722131B2 (en) 2010-09-07 2014-05-13 Dsm Nutritional Products Ag Comestible emulsions
TR201905477T4 (tr) 2011-01-24 2019-05-21 Anterios Inc Nano-parçacık bileşimler.
US20120328549A1 (en) 2011-01-24 2012-12-27 Anterios, Inc. Oil compositions
EP3689331A1 (en) 2011-01-24 2020-08-05 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses thereof
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
JP6182540B2 (ja) * 2012-12-21 2017-08-16 株式会社 先端医療開発 組成物及び飲食物
BR112015023340B1 (pt) * 2013-03-15 2020-05-05 Leading Edge Innovations Llc composição substancialmente livre de tensoativo, método para aplicar agentes de modificação estética e método para transmitir uma propriedade tátil, olfativa ou visual à pele, ao cabelo ou à superfície de mucosa
US20140322428A1 (en) 2013-03-15 2014-10-30 Leading Edge Innovations, LLC Compositions having an oil-in-water dispersion of submicron particles to enhance foods and beverages
TWI522115B (zh) * 2013-10-09 2016-02-21 The delivery of the active ingredient and its application
CA3002989C (en) * 2013-10-14 2021-03-16 Nanosphere Health Sciences, Llc Nanoparticle compositions and methods as carriers of nutraceutical factors across cell membranes and biological barriers
JP2017506671A (ja) * 2014-02-14 2017-03-09 ホアン，ジンジュン ナノエマルジョン送達系の組成物
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
CA2962900C (en) * 2014-09-29 2021-08-24 Barrie Tan Non-synthetic emulsion-based lipid formulations and methods of use
WO2016100228A2 (en) 2014-12-15 2016-06-23 Nanosphere Health Sciences, Llc Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of nsaids
US10596117B1 (en) * 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
CA2979184C (en) 2015-03-10 2020-09-08 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
CN106551902B (zh) * 2015-09-17 2020-07-03 阿赖耶识（上海）生物技术有限公司 一种高稳定的非囊泡型纳米颗粒及其在治疗微生物感染中的应用
EP3360576B1 (en) * 2015-10-08 2022-09-28 NOF Corporation O/w type emulsion
US20170143011A1 (en) 2015-11-25 2017-05-25 Pepsico, Inc. Beverage nanoemulstions produced by high shear processing
GB201618350D0 (en) * 2016-10-31 2016-12-14 Ip Science Ltd Methods and compositions comprising carotenoids
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents
CN108576778A (zh) * 2018-02-06 2018-09-28 华南农业大学 一种食品级赋形剂纳米乳液及其制备方法与应用
US10206417B1 (en) * 2018-06-07 2019-02-19 King Saud University Guava seed (Psidium guajava) nanoparticles as antibacterial agent
CN117695226A (zh) 2018-12-11 2024-03-15 迪斯拉普申实验室公司 用于递送治疗剂的组合物及其使用方法和制备方法
US11465107B2 (en) * 2019-01-31 2022-10-11 Hong Ngoc Thi Dang Process for producing a nano omega-3 microemulsion system
US11622947B2 (en) 2019-05-31 2023-04-11 American River Nutrition, Llc Compositions comprising quillaja extract and methods of preparations and use thereof
CN111296730A (zh) * 2020-03-06 2020-06-19 广州市食品工业研究所有限公司 一种稳定性好的叶黄素纳米乳液及其制备方法
CN111544387B (zh) * 2020-04-18 2021-11-02 内蒙古医科大学 一种复方槲皮素抗菌纳米乳及其制备方法
US20220054414A1 (en) * 2020-08-19 2022-02-24 Readymix Foods Corp. Nanoemulsion Compositions Comprising Saponins for Increasing Bioavailability
CN112042928B (zh) * 2020-08-31 2022-06-10 华南理工大学 一种以多羟基醇作为分子伴侣协同高效制备蛋白基纳米乳液的方法及制得的蛋白基纳米乳液
WO2024006539A1 (en) * 2022-07-01 2024-01-04 Vitakey Inc. Nutraceutical particles

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH587021A5 (pt) * 1974-06-07 1977-04-29 Nestle Sa
US4908154A (en) * 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US4533254A (en) * 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JPH0798740B2 (ja) * 1987-10-28 1995-10-25 日本新薬株式会社 薬物担体
US5651991A (en) * 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
IL88076A (en) 1987-10-28 1993-01-14 Nippon Shinyaku Co Ltd Fat emulsions as drug carriers
CH677886A5 (pt) * 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5652274A (en) 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
EP0594612B2 (en) * 1991-05-03 2010-02-24 Raisio Nutrition Ltd. Process for the preparation of a substance comprising a beta-sitostanol fatty acid ester or a mixture thereof
US7384918B2 (en) * 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US6939852B2 (en) * 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
EP0571677A1 (en) 1992-05-29 1993-12-01 Unilever Plc Aqueous parfume oil microemulsions
EP0572080B1 (en) 1992-05-29 1995-11-15 Quest International B.V. Aqueous perfume oil microemulsions
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
JP2867208B2 (ja) * 1993-07-27 1999-03-08 光洋精工株式会社 クラッチレリーズ軸受
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
JPH07285863A (ja) * 1994-02-25 1995-10-31 Takeda Chem Ind Ltd 注射剤組成物およびその製造方法
AU682580B2 (en) 1994-02-25 1997-10-09 Takeda Chemical Industries Ltd. Injectable emulsions containing antifungal triazole derivatives
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
ES2078190B1 (es) * 1994-05-20 1996-08-01 Cusi Lab Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
US5843334A (en) 1994-06-20 1998-12-01 Nippon Shinyaku Co., Ltd. Method of producing emulsions and an emulsification apparatus
US5672358A (en) * 1994-06-21 1997-09-30 Ascent Pharmaceuticals, Inc. Controlled release aqueous emulsion
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
FR2730932B1 (fr) * 1995-02-27 1997-04-04 Oreal Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
FR2755854B1 (fr) * 1996-11-15 1998-12-24 Oreal Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr) * 1997-03-18 2000-03-10 Oreal Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
US5994414A (en) * 1997-04-28 1999-11-30 Avon Products, Inc. Water-thin emulsion formed by high pressure homogenization process
GB9708066D0 (en) * 1997-04-22 1997-06-11 Woolcombers Group Plc Compositions and their use
EP1027033B1 (en) 1997-05-14 2009-07-22 The University Of British Columbia High efficiency encapsulation of nucleic acids in lipid vesicles
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
ES2268567T5 (es) * 1997-07-15 2010-11-02 The Regents Of The University Of Colorado Uso de terapia de neurotoxinas para el tratamiento de la retencion urinaria.
JPH1144594A (ja) * 1997-07-25 1999-02-16 Yamatake Honeywell Co Ltd 圧力検出器
US6007856A (en) 1997-08-08 1999-12-28 The Procter & Gamble Company Oil-in-water dispersions of β-carotene and other carotenoids stable against oxidation prepared from water-dispersible beadlets having high concentrations of carotenoid
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
EP1080720A4 (en) 1998-03-05 2002-06-05 Nippon Shinyaku Co Ltd FAT EMULSIONS FOR INHALATIVE ADMINISTRATION
DE59914485D1 (de) * 1998-03-30 2007-10-18 Mibelle Ag Cosmetics Verwendung von Nanoemulsionen zur Bestimmung der Biokompatibilität von lipophilen Stoffen im Zellkultur-Test und dafür geeignete Nanoemulsionen
FI111513B (fi) * 1998-05-06 2003-08-15 Raisio Benecol Oy Uudet fytosteroli- ja fytostanolirasvahappoesterikoostumukset, niitä sisältävät tuotteet sekä menetelmät niiden valmistamiseksi
US5932562A (en) * 1998-05-26 1999-08-03 Washington University Sitostanol formulation to reduce cholesterol absorption and method for preparing and use of same
GB9818548D0 (en) * 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6242001B1 (en) * 1998-11-30 2001-06-05 Mcneil-Ppc, Inc. Method for producing dispersible sterol and stanol compounds
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
CZ20012038A3 (cs) 1998-12-23 2001-09-12 Idea Ag Zdokonalený přípravek pro topické, neinvazivní použití in vivo
FR2787728B1 (fr) * 1998-12-23 2001-01-26 Oreal Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2788007B1 (fr) 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
CA2377422A1 (en) 1999-08-04 2001-02-15 Idea Ag Periodic structures comprising lipids, polyelectrolytes, and structure- inducing soluble oligovalent linkers, and biological use thereof
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
FR2804015B1 (fr) * 2000-01-21 2005-12-23 Oreal Nanoemulsion contenant des lipides amphiphiles et un polymere non ionique et utilisations
ES2327901T3 (es) * 2000-03-23 2009-11-05 Basf Catalysts Llc Metodo para preparar dispersiones que contienen ingredientes fisiologicamente activos a alta presion/alta cizalla.
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
FR2809010B1 (fr) * 2000-05-22 2002-07-12 Oreal Nanoemulsion a base de polymeres anioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
US6670322B2 (en) 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20020155084A1 (en) * 2000-06-02 2002-10-24 The Regents Of The University Of The Michigan Nanoemulsion formulations
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
FR2811561B1 (fr) * 2000-07-13 2003-03-21 Oreal Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase
US20040220100A1 (en) 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US7255865B2 (en) * 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
WO2002051390A2 (en) * 2000-12-27 2002-07-04 Ares Trading S.A. Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
FI20010115A0 (fi) 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
FR2819427B1 (fr) * 2001-01-18 2003-04-11 Oreal Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US20040048836A1 (en) * 2001-03-23 2004-03-11 Wilmott James M Method for preparing high pressure/ high shear dispersions containing physiologically active ingredients
JP4444565B2 (ja) * 2001-03-30 2010-03-31 カラー アクセス，インコーポレイティド 新規ナノエマルション
KR100463167B1 (ko) 2001-04-13 2004-12-23 주식회사 태평양 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
CA2451923C (en) * 2001-07-27 2009-10-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US6861066B2 (en) * 2002-03-11 2005-03-01 Health Plus International Inc. Method for the delivery of a biologically active agent
US6688311B2 (en) * 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US6623780B1 (en) * 2002-03-26 2003-09-23 Cargill, Inc. Aqueous dispersible sterol product
US20040115159A1 (en) * 2002-03-29 2004-06-17 Tadlock Charles C Novel nanoemulsions
US7459164B2 (en) * 2002-05-28 2008-12-02 Botulinum Toxin Research Associates, Inc. Composition for therapeutic and cosmetic botulinum toxin
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
AU2003231878A1 (en) 2002-05-31 2003-12-19 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
AU2003241478A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate sterol formulations and sterol combinations
US6996748B2 (en) * 2002-06-29 2006-02-07 Intel Corporation Handling faults associated with operation of guest software in the virtual-machine architecture
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
WO2004024786A1 (en) * 2002-09-12 2004-03-25 3M Innovative Properties Company Fluoroelastomers having low temperature characteristics and solvent resistance
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US7329688B2 (en) * 2002-12-17 2008-02-12 Soft Gel Technologies, Inc. Natural vitamin E compositions with superior antioxidant potency
BR0316871A (pt) * 2002-12-20 2005-10-18 Botulinum Toxin Res Ass Inc Composições farmacêuticas aperfeiçoadas de toxina botulìnica
JP4469846B2 (ja) 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
CA2515083A1 (en) * 2003-02-05 2004-08-26 Amphora Discovery Corporation Topical delivery of cosmetic agents
US20060153876A1 (en) * 2003-02-24 2006-07-13 Ira Sanders Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20040247623A1 (en) 2003-03-24 2004-12-09 Roger Cady Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
DK1613346T3 (da) * 2003-04-04 2013-01-07 Pah Usa 15 Llc Mikrofluidiske olie-i-vand-emulsioner og vaccinesammensætninger
US20050208083A1 (en) * 2003-06-04 2005-09-22 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
WO2005027872A2 (en) * 2003-06-04 2005-03-31 Nanobio Corporation Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
WO2004112821A1 (ja) * 2003-06-20 2004-12-29 Santen Pharmaceutical Co., Ltd. 筋緊張亢進性疾患の治療剤
JPWO2005013938A1 (ja) 2003-08-06 2006-09-28 エーザイ株式会社 薬物超微粒子の製造法及び製造装置
EP1651276A4 (en) * 2003-08-08 2009-05-06 Barnes Jewish Hospital EMULSION PARTICLES FOR IMAGING AND THERAPY AND USE METHOD THEREFOR
CH715855B1 (de) * 2003-08-28 2020-08-14 Mibelle Ag Zubereitung bestehend aus mindestens zwei Nanoemulsionen.
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
WO2005042539A1 (en) * 2003-10-29 2005-05-12 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
EP1547674A1 (en) 2003-12-23 2005-06-29 MediGene Oncology GmbH Method for producing colloidal nanoparticles
US6974579B2 (en) 2004-01-08 2005-12-13 Allergan, Inc. Methods for treating vascular disorders
US8182834B2 (en) 2004-01-23 2012-05-22 Camurus Ab Ternary non-lamellar lipid compositions
AU2004316985A1 (en) * 2004-02-23 2005-09-15 The Texas A & M University System Antioxidant compositions and methods of use thereof
ES2691498T3 (es) * 2004-03-03 2018-11-27 Revance Therapeutics, Inc. Aplicación tópica y liberación transdérmica de toxinas botulínicas
US20050214325A1 (en) * 2004-03-26 2005-09-29 Vvii Newco 2003, Inc. Compositions and methods to increase the effect of a neurotoxin treatment
TW200603843A (en) 2004-04-20 2006-02-01 Technology Dev Company Ltd Tissue enhancement implant and method
US20050249686A1 (en) * 2004-04-27 2005-11-10 Francoise Pataut Cosmetic composition free of water comprising fatty acid esters, petrolatum oil and non-ionic polymers
US7591806B2 (en) 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US7228259B2 (en) * 2004-06-30 2007-06-05 Lucent Technologies Inc. Method and apparatus for structure-preserving reduced-order modeling
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
CA2578250C (en) * 2004-07-26 2013-03-05 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
JP2008519784A (ja) 2004-11-12 2008-06-12 イデア アクチェンゲゼルシャフト 皮膚状態の治療における拡張表面凝集体
DK1853303T3 (en) 2005-02-14 2016-02-29 Dpm Therapeutics Corp STABILIZED COMPOSITIONS FOR TOPIC ADMINISTRATION AND PROCEDURES FOR PREPARING IT
CA2494473C (en) 2005-02-14 2007-06-26 Dpm Therapeutics Corp. Stabilized protein compositions for topical administration and methods of making same
CN102499981B (zh) 2005-03-03 2016-08-03 雷文斯治疗公司 用于局部施用和经皮肤递送肉毒杆菌毒素的组合物和方法
WO2006138127A2 (en) 2005-06-14 2006-12-28 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
CA2618655C (en) 2005-07-18 2015-12-22 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
WO2008051186A2 (en) * 2005-08-09 2008-05-02 Nanobio Corporation Nanoemulsion containing compositions having ant i -inflammatory activity
WO2007035311A2 (en) 2005-09-16 2007-03-29 University Of Massachusetts Lowell Anti-oxidant synergy formulation nanoemulsions to treat cancer
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
DK3144013T3 (en) 2005-12-01 2019-03-04 Univ Massachusetts Lowell Botulinum nanoemulsions
US20070178121A1 (en) * 2006-01-27 2007-08-02 Allergan, Inc. Methods for enhancing skin treatments
WO2007103555A2 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
US20100183726A1 (en) * 2006-08-02 2010-07-22 Robert Nicolosi Compositions and methods for treating cancer with dacarbazine nanoemulsions
CA2719803A1 (en) 2008-03-28 2009-10-01 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
US20110206736A1 (en) * 2008-09-23 2011-08-25 Thomas Jefferson University Cancer Vaccines Against Mucosal Antigens and Methods of Making and Using the Same

Also Published As

Publication number Publication date
EP1919447A2 (en) 2008-05-14
JP5368793B2 (ja) 2013-12-18
CA2618655C (en) 2015-12-22
US10016364B2 (en) 2018-07-10
US20150335574A1 (en) 2015-11-26
AU2006346369B2 (en) 2013-02-21
CA2618655A1 (en) 2008-01-24
IL243260A0 (en) 2016-02-29
WO2008010788A9 (en) 2008-03-06
JP2009501802A (ja) 2009-01-22
WO2008010788A2 (en) 2008-01-24
IL188666A (en) 2016-03-31
US20080274195A1 (en) 2008-11-06
KR20130079645A (ko) 2013-07-10
IL188666A0 (en) 2011-08-01
KR20080058326A (ko) 2008-06-25
BRPI0613631A2 (pt) 2011-01-18
CN101384247A (zh) 2009-03-11
EP1919447A4 (en) 2012-10-31
WO2008010788A3 (en) 2008-10-23
CN101384247B (zh) 2013-05-22
CN103315954A (zh) 2013-09-25
KR101430767B1 (ko) 2014-08-19
JP2013028615A (ja) 2013-02-07
AU2006346369A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
BRPI0613631A8 (pt) nanoemulsão e método,
Zhuo et al. One-step synthesis of high quantum-yield and excitation-independent emission carbon dots for cell imaging
Tabet et al. Adverse effects of industrial multiwalled carbon nanotubes on human pulmonary cells
Hu et al. Multifunctional carbon dots with high quantum yield for imaging and gene delivery
Adamcik et al. Observation of single‐stranded DNA on mica and highly oriented pyrolytic graphite by atomic force microscopy
Hai et al. Folic acid encapsulated graphene quantum dots for ratiometric pH sensing and specific multicolor imaging in living cells
Gillen et al. Non-covalent methods of engineering optical sensors based on single-walled carbon nanotubes
Lei et al. Non-covalent decoration of carbon dots with folic acid via a polymer-assisted strategy for fast and targeted cancer cell fluorescence imaging
Zou et al. Micro/nano-structured ultrathin g-C3N4/Ag nanoparticle hybrids as efficient electrochemical biosensors for L-tyrosine
Venkatachalam et al. Er 3+‐Doped Y 2 O 3 Nanophosphors for Near‐Infrared Fluorescence Bioimaging Applications
Zhang et al. Chloroplasts-mediated biosynthesis of nanoscale Au-Ag alloy for 2-butanone assay based on electrochemical sensor
Kang et al. Comparison of the biological activity between ultrafine and fine titanium dioxide particles in RAW 264.7 cells associated with oxidative stress
Frasconi et al. Highly surface functionalized carbon nano-onions for bright light bioimaging
Wang et al. Gelatin‐Assisted synthesis of vaterite nanoparticles with higher surface area and porosity as anticancer drug containers in vitro
Jagiello et al. Production of graphene composite by direct graphite exfoliation with chitosan
BRPI0508134A (pt) sistema transportador, uso do sistema transportador e método para a produção de um sistema transportador
Kiyotake et al. Conductive and injectable hyaluronic acid/gelatin/gold nanorod hydrogels for enhanced surgical translation and bioprinting
Zhang et al. Cell nucleus targeting for living cell extraction of nucleic acid associated proteins with intracellular nanoprobes of magnetic carbon nanotubes
Aramesh et al. Conformal nanocarbon coating of alumina nanocrystals for biosensing and bioimaging
Yan et al. On-demand generation of singlet oxygen from a smart graphene complex for the photodynamic treatment of cancer cells
Attri et al. Interaction studies of carbon nanomaterials and plasma activated carbon nanomaterials solution with telomere binding protein
Tang et al. The role of electrostatic potential polarization in the translocation of graphene quantum dots across membranes
Lan et al. Sensitive and selective turn off-on fluorescence detection of heparin based on the energy transfer platform using the BSA-stabilized au nanoclusters/amino-functionalized graphene oxide hybrids
Tu et al. Adsorption performance of boron nitride nanomaterials as effective drug delivery carriers for anticancer drugs based on density functional theory
Ma et al. Design and synthesis of highly fluorescent and stable fullerene nanoparticles as probes for folic acid detection and targeted cancer cell imaging

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL